Case 1: A 36-year-old mother of three children with a personal and family history of colonic polyps who presented with an obstructive rectal adenocarcinoma and diffuse metastatic disease in the liver, lung, bone, peritoneum and mesenteric and inguinal lymph nodes(from the practice of Dr Daniel J Moriarty)

Case 2: A 64-year-old woman with persistent rectal bleeding and severe anemia who presented with locally advanced rectal cancer (from the practice of Dr Fernando T Miranda)

Case 3: A 51-year-old man who was treated with the Roswell Park regimen in 2001 for a T3/N1 ascending colon carcinoma, which recurred four years later with retroperitoneal lymphadenopathy and multiple pulmonary nodules (from the practice of Dr Kapisthalam S Kumar)

Case 4: A 65-year-old man with a history of hypertension who presented with a sigmoid mass and multiple hepatic metastases (from the practice of Dr Ghassan Jano)

Case 5: A 67-year-old woman who was diagnosed with a T4/N0/M0 tumor with central ulceration in the transverse colon and a nodule in the overlying omentum (from the practice of Dr Barbara G Fallon)

Case 6: A 47-year-old man with multiple surgical resections and systemic therapies for recurrent metastatic colorectal cancer to diverse organ sites (from the practice of Dr William G Reeves)

PET scans demonstrating decreased activity at primary () and metastatic () sites of rectal carcinoma following treatment with FOLFOX and bevacizumab: Bevacizumab was then discontinued, and the patient was treated with radiation therapy to the rectum and continuous 5-FU. The patient was then switched to capecitabine plus bevacizumab. A repeat PET-CT study six months later revealed continued tumor response in the liver. The CEA, which was over 3,000 ng/mL at diagnosis, is now 3 ng/mL.